Diabetic neuropathy is a common and disabling condition, with the most frequent form being distal symmetric polyneuropathy (DSP). It is characterized by numbness, tingling, and pain in the feet and legs, often leading to significant physical and mental health impacts. The prevalence of diabetic neuropathy is high, with up to 50% of diabetics developing it over time. While glucose control is the only disease-modifying therapy, pain management is crucial for improving quality of life. Current treatments include anticonvulsants and antidepressants for pain relief. However, the lack of disease-modifying therapies highlights the need for identifying new modifiable risk factors, such as components of metabolic syndrome, which are increasingly linked to neuropathy. Type 1 diabetes shows a more significant reduction in neuropathy with tight glucose control compared to type 2 diabetes. Despite this, glucose control alone is not sufficient for type 2 patients, suggesting the need for additional therapies. The pathophysiology of diabetic neuropathy involves hyperglycemia, dyslipidemia, and insulin resistance, which contribute to nerve damage through various mechanisms, including oxidative stress, inflammation, and mitochondrial dysfunction. Metabolic syndrome components, including pre-diabetes, are potential risk factors for neuropathy, and further research is needed to clarify their role. Pain management in diabetic neuropathy (DNP) is a major challenge, with effective treatments including anticonvulsants, antidepressants, and opioids. Guidelines recommend these medications based on evidence from clinical trials. However, many patients with DNP are not adequately treated, highlighting the need for better screening and management strategies. Treatment algorithms suggest first-line therapies such as gabapentin, pregabalin, tricyclic antidepressants, and SNRIs. Second-line options include opioids and tramadol, though their long-term use is associated with risks. The role of metabolic syndrome in neuropathy is an area of growing interest, with studies suggesting a link between its components and neuropathy. However, the evidence is conflicting, and further research is needed to determine causality and develop new treatments. Overall, the management of diabetic neuropathy requires a multifaceted approach, including glucose control, pain management, and addressing modifiable risk factors. Future studies should focus on understanding the mechanisms linking metabolic syndrome to neuropathy and developing targeted therapies.Diabetic neuropathy is a common and disabling condition, with the most frequent form being distal symmetric polyneuropathy (DSP). It is characterized by numbness, tingling, and pain in the feet and legs, often leading to significant physical and mental health impacts. The prevalence of diabetic neuropathy is high, with up to 50% of diabetics developing it over time. While glucose control is the only disease-modifying therapy, pain management is crucial for improving quality of life. Current treatments include anticonvulsants and antidepressants for pain relief. However, the lack of disease-modifying therapies highlights the need for identifying new modifiable risk factors, such as components of metabolic syndrome, which are increasingly linked to neuropathy. Type 1 diabetes shows a more significant reduction in neuropathy with tight glucose control compared to type 2 diabetes. Despite this, glucose control alone is not sufficient for type 2 patients, suggesting the need for additional therapies. The pathophysiology of diabetic neuropathy involves hyperglycemia, dyslipidemia, and insulin resistance, which contribute to nerve damage through various mechanisms, including oxidative stress, inflammation, and mitochondrial dysfunction. Metabolic syndrome components, including pre-diabetes, are potential risk factors for neuropathy, and further research is needed to clarify their role. Pain management in diabetic neuropathy (DNP) is a major challenge, with effective treatments including anticonvulsants, antidepressants, and opioids. Guidelines recommend these medications based on evidence from clinical trials. However, many patients with DNP are not adequately treated, highlighting the need for better screening and management strategies. Treatment algorithms suggest first-line therapies such as gabapentin, pregabalin, tricyclic antidepressants, and SNRIs. Second-line options include opioids and tramadol, though their long-term use is associated with risks. The role of metabolic syndrome in neuropathy is an area of growing interest, with studies suggesting a link between its components and neuropathy. However, the evidence is conflicting, and further research is needed to determine causality and develop new treatments. Overall, the management of diabetic neuropathy requires a multifaceted approach, including glucose control, pain management, and addressing modifiable risk factors. Future studies should focus on understanding the mechanisms linking metabolic syndrome to neuropathy and developing targeted therapies.